Entecavir for patients with lamivudine-resistant chronic hepatitis B virus infection-Reference-Cited by-同舟云学术

Entecavir for patients with lamivudine-resistant chronic hepatitis B virus infection

Published:2017-01-06 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Mok Shaffer¹,Mohan Sachin²,Hunter Krystal M³,Wang Yize R¹,Judge Thomas A¹

Affiliation:

1. Cooper University Hospital at Rowan University School of Medicine; Department of Internal Medicine, Division of Gastroenterology and Liver Diseases; 501 Fellowship Road Suite 101 Mt. Laurel NJ USA 08054

2. Cooper University Hospital; Department of Internal Medicine; 3rd floor, 401 Haddon Avenue Camden NJ USA 08103

3. Cooper University Hospital; Biostatistics/Research Institute; 1 Cooper Plaza Camden NJ USA 08103

Publisher

Wiley

Subject

Pharmacology (medical)

Reference97 articles.

1. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group;Allen;Hepatology (Baltimore, Md.),1998

2. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance;Andreone;Journal of Viral Hepatitis,2004

3. Entecavir in lamivudine-refractory chronic hepatitis B infection: a meta-analysis;Ang;Hepatology International,2010

4. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update;Liaw;Hepatology International,2012

5. Grading quality of evidence and strength of recommendations;Atkins;BMJ (Clinical Research Ed.),2004

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emtricitabine for adults with lamivudine-resistant chronic hepatitis B virus infection;Cochrane Database of Systematic Reviews;2017-01-06